SWSimon Van Wambeke

Simon Van Wambeke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simon Van Wambeke has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk and Benefit for Basket Trials in Oncology: A Systematic Review and Meta-Analysis

    by Katarzyna Klas, Karolina Strzebonska, Lucja Zaborowska, Tomasz Krawczyk, Alicja Włodarczyk, Urszula Bąk-Kuchejda, Maciej Polak, Simon Van Wambeke, Marcin Waligora

    Background Oncology research is increasingly adopting new clinical trial models that implement the concept of precision medicine. One of these is the basket clinical trial design. Basket clinical trials allow new treatments to be evaluated across multiple tumor types. Patients recruited to basket clinical trials share certain molecular characteristics of their cancer that are predictive of clinical benefit from the experimental treatment. Objective Our aim was to describe the risks and benefits of basket clinical trials in oncology. Methods Our study was prospectively registered in PROSPERO (CRD42023406401). We systematically searched PubMed, Embase, and ClinicalTrials.gov for reports of basket clinical trials in oncology published between 1 January, 2001, and 14 June, 2023. We measured the risk by treatment-related adverse events (grades 3, 4, and 5), and the benefit by objective response rate. We also extracted and analyzed data on progression-free survival and overall survival. When possible, data were meta-analyzed. Results We included 126 arms of 75 basket clinical trials accounting for 7659 patients. The pooled objective response rate was 18.0% (95% confidence interval [CI] 14.8–21.1). The rate of treatment-related death was 0.7% (95% CI 0.4–1.0), while 30.4% (95% CI 24.2–36.7) of patients experienced grade 3/4 drug-related toxicity. The median progression-free survival was 3.1 months (95% CI 2.6–3.9), and the median overall survival was 8.9 months (95% CI 6.7–10.2). Conclusions Our results provide an empirical basis for communicating about the risks and benefits of basket clinical trials and for refining new models of clinical trials applied in precision medicine.


  • Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?

    by Simon Van Wambeke, Francisco Emilio Vera-Badillo, Bishal Gyawali

    “A serious look at what counts as a standard of care control arm in metastatic castration resistant prostate cancer. Is ARTA after ARTA good enough?”